Organization
Amgen Inc., Thousand Oaks, United States of America
3 abstracts
Abstract
APREMILAST REDUCES AXIAL INFLAMMATION IN PATIENTS WITH PSORIATIC ARTHRITIS AS ASSESSED BY CANDEN MRI SCORING: RESULTS FROM THE PHASE 4 MOSAIC STUDYOrg: Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, Department of Medicine, University of Alberta, Edmonton, Canada, Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Canada, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark,
Abstract
APREMILAST TREATMENT IN EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS (PSA) IMPROVES CLINICAL AND PATIENT-REPORTED OUTCOMES FOR UP TO 48 WEEKS - DATA FROM THE FOREMOST STUDYOrg: Sorbonne Université and Pitié-Salpêtrière Hospital, Paris, France, University of Oxford, Oxford, United Kingdom, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Canada, University of Pennsylvania Hospital, Pennsylvania, United States of America, Aurora Health Care, Wisconsin, United States of America,
Abstract
BIOSIMILAR CANDIDATE ABP 501: ADDITIONAL EFFICACY ANALYSES FROM THE PHASE 3 STUDY Org: 1Metroplex Clinical Research Center, dallas, Amgen Inc., Thousand Oaks, United States of America,